Jeffrey J Crowley MD

Dermatologic Surgery

Bakersfield Dermatology and Skin Cancer Medical Group

5101 Commerce DrSte 101Bakersfield, CA 93309
Phone+1 661-327-3756
Fax+1 661-327-2332

Dr. Crowley is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Crowley's full profile Already have an account?

Summary

Dr. Crowley earned his BS, MS, and MD’s degrees from Stanford University in biological science and continued at Stanford where he also completed dermatology residency and served as Chief Resident.

Dr. Crowley has served as clinical faculty for both the University of California, Los Angeles, and Stanford University Departments of Dermatology and has been principal investigator for over 80 Phase 2 and 3 clinical trials for psoriasis, atopic dermatitis and hidradenitis suppurativa. His areas of interest include clinical trial design and all aspects of inflammatory skin disease.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Dermatology, 1992 - 1995
Stanford University School of MedicineClass of 1992

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1993 - 2027
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NexTech Practice 2011, NexTech Systems, LLC, 2012, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FAAD) American Academy of Dermatology

Clinical Trials

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis Start of enrollment: 2019 Oct 29
COMPLETED
PHASE3
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. Start of enrollment: 2020 Feb 03
COMPLETED
PHASE3
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) Start of enrollment: 2020 Jun 15
COMPLETED
PHASE3

Publications & Presentations

PubMed

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis.
Jeffrey Crowley, Eingun James Song, Linda Stein-Gold, Paolo Gisondi, Christopher G Bunick
Dermatology and Therapy. 2026-08-01
12 citations
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestation...
Bruce Strober, Hervé Bachelez, Jeffrey Crowley, Boni E Elewski, Melinda Gooderham
Journal of the European Academy of Dermatology and Venereology. 2024-05-01
3 citations
Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) vers...
Melinda Gooderham, Ronald Vender, Jeffrey Crowley, H Chih-Ho Hong, Meghan Feely
Dermatology and Therapy. 2024-02-01

Authored Content

A Brief Guide to Pustular Psoriasis for Primary Care ProvidersSeptember 2020

Press Mentions

Long-Term Benefit in Psoriasis with Monoclonal AntibodyOctober 15th, 2019
Antibodies Towards High-Density Lipoprotein Components in Patients with PsoriasisOctober 14th, 2019